6.5(top 5%)
impact factor
4.5K(top 5%)
papers
110.8K(top 5%)
citations
110(top 5%)
h-index
6.9(top 5%)
extended IF
5.6K
all documents
129.5K
doc citations
172(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary EmbolismBlood Advances20201,144
2American Society of Hematology 2019 guidelines for immune thrombocytopeniaBlood Advances20191,093
3Updated international consensus report on the investigation and management of primary immune thrombocytopeniaBlood Advances2019924
4American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancerBlood Advances2021715
5American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patientsBlood Advances2018664
6American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopeniaBlood Advances2018611
7American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patientsBlood Advances2019497
8American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancyBlood Advances2018477
9ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand diseaseBlood Advances2021444
10American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapyBlood Advances2018439
11American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolismBlood Advances2018399
12American Society of Hematology 2020 guidelines for sickle cell disease: transfusion supportBlood Advances2020391
13Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaBlood Advances2020388
14Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaBlood Advances2020386
15American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolismBlood Advances2018356
16Epidemiology of AL amyloidosis: a real-world study using US claims dataBlood Advances2018352
17A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaBlood Advances2020347
18American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19Blood Advances2021347
19American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adultsBlood Advances2020344
20Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaBlood Advances2020342
21American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic painBlood Advances2020342
22ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand diseaseBlood Advances2021300
23A neutrophil activation signature predicts critical illness and mortality in COVID-19Blood Advances2021291
24Targeted deep sequencing in polycythemia vera and essential thrombocythemiaBlood Advances2016281
25Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United StatesBlood Advances2017269
26Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015Blood Advances2017258
27Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesBlood Advances2020241
28Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Blood Advances2022226
29First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumabBlood Advances2020223
30The clinical spectrum of Erdheim-Chester disease: an observational cohort studyBlood Advances2017222
31Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics studyBlood Advances2017219
32High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaBlood Advances2020214
33First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemiaBlood Advances2019213
34Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1Blood Advances2021210
35Targeted deep sequencing in primary myelofibrosisBlood Advances2016207
36Pharmacologic control of CAR-T cell function using dasatinibBlood Advances2019207
37Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaBlood Advances2017204
38Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaBlood Advances2020204
39T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myelomaBlood Advances2019200
40Diversity of peripheral blood human NK cells identified by single-cell RNA sequencingBlood Advances2020195
41Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversityBlood Advances2018192
42Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseasesBlood Advances2017191
43A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBlood Advances2020184
44US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALLBlood Advances2016183
45Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLHBlood Advances2017183
46Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk featuresBlood Advances2020183
47Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphomaBlood Advances2018178
48International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseBlood Advances2020178
49IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cellsBlood Advances2017177
50CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyBlood Advances2019177